Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Part of paid clinical trials in Hoover, Alabama.
- Sponsor
- AbbVie
- Study ID
- NCT05216263
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Atogepant — DRUGOral Tablet
Study Details
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the efficacy of add-on atogepant for migraine prevention. Adverse events and change in disease activity will be monitored. Atogepant is an investigational drug being developed to prevent chronic migraine. Approximately 75 adult participants will be enrolled at approximately 30 sites in the United States. All participants will receive atogepant oral tablet once a day (QD) during the 24-week treatment period, in addition to their standard of care Botox. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Key Dates
- Start date
- Mar 22, 2022
- Status verified
- May 2025
- Primary completion
- May 2, 2025
- Completion
- May 2, 2025
Study Design
- Enrollment
- 75 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AtogepantParticipants will receive atogepant once a day (QD) during the 24-week treatment period.
Primary Outcome Measure
Number of Participants With Adverse Events (AEs) [ Time Frame: Up to approximately 28 Weeks ]
Locations (29)
Find similar trials in Hoover, AL
Related Studies
- Analysis of Headache Chronification With Imaging, Deep Phenotyping, and ProteomicsRecruiting · Stanford University · Stanford, California
- Determining the Utility of a Behavioral Intervention in Chronic MigraineRecruiting · Mayo Clinic · Phoenix, Arizona
- BOTOX® vs. XEOMIN® for Chronic MigrainePHASE3 · Recruiting · Naval Medical Center Camp Lejeune · Jacksonville, North Carolina
- Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)Recruiting · University of Michigan · Ann Arbor, Michigan